ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership

July 10, 1992

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

In Brief: Delores Esparza President Elect Of ONS; Brown Demands Jako Retract “Insulting Remarks”

May 13, 1988

NCCS Networker Volume 1 Issue 2, Summer 1987

June 13, 1987

NCI-Approved Clinical Trials

April 29, 2005

NCI Resumes Clinical Education Grants

March 18, 1983